Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reveal a nuanced debate about the effectiveness of valsartan, with posts referencing historical trials like Val-HeFT and highlighting conflicting evidence—such as one post mentioning that valsartan did not reduce mortality, while others focus on reduced hospitalizations. The tone varies from critical to analytical, showing both skepticism and engagement in interpreting trial outcomes, which supports the assigned scores.
Discussions reflect mixed opinions about the study's findings, especially regarding valsartan's efficacy in reducing mortality, with some posts challenging or questioning its conclusions.
Posts show moderate to high interest, as users discuss specific trials, compare drugs, and analyze implications for treatment decisions.
Many posters deeply analyze trial results, cite studies, and engage in detailed debates, indicating a high level of intellectual engagement.
Discussions highlight the significance of the study in shaping treatment choices and understanding drug effects, although some debate about the overall benefits reduces perceived universal impact.
Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOLVD Valsartan was never proven to ↓ mortality & would have been considered a straw man comparator...perhaps by the very same people
バルサルタンvsプラセボのデザインだけど、ベースラインを見たら92%の人がACE-Iを使っているやん。 Val-HeFT Cohn JN,et al.N Engl J Med. 2001 Dec 6;345(23):1667-75.PMID:11759645 https://t.co/Gbd90TjGeP
@GiuseppeGalati_ @hvanspall @MarcoMetra @MicheleSenni @DrRajivsankar @rahatheart1 @AndreasGevaert @DrMarthaGulati @ShelleyZieroth @mirvatalasnag @DrNasrien @AspriAlexia @KTamirisaMD @MKIttlesonMD @HanCardiomd @pumpinghearts @IC_LaFe @ehj_ed @Vilavaite https://t.co/NHOrsvycqI #CardioTwitter
@roi_cal @doctorchecho @mgalandejuana En absoluto. Valsartan no redujo mortalidad por todas las causas: https://t.co/jrQFL7ZEkk La comparación de SV con IECA es pertinente. ARA2 solo son alternativa a IECA en caso de tos en IC-FEr; por no demostrar reducción de mortalidad por todas las causas. Los IECA si. Y SV más.
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
Learn about the optimal medication prescriptions for patients with HFrEF based on the 2021 ESC Guidelines. This video discusses vericiguat, a promising new medication shown to reduce cardiovascular events in high-risk…
This video explores the optimal medication strategies for patients with heart failure and reduced ejection fraction, in accordance with the 2021 ESC Guidelines. It examines the efficacy of new treatments, including…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
RT @mvaduganathan: Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOL…
Enalapril was the best studied RASi & was tested at doses *higher* than those proven to ↓ mortality in #CONSENSUS & #SOLVD Valsartan was never proven to ↓ mortality & would have been considered a straw man comparator...perhaps by the very same people
@roi_cal @doctorchecho @mgalandejuana En absoluto. Valsartan no redujo mortalidad por todas las causas: https://t.co/jrQFL7ZEkk La comparación de SV con IECA es pertinente. ARA2 solo son alternativa a IECA en caso de tos en IC-FEr; por no demostrar reducción de mortalidad por todas las causas. Los IECA si. Y SV más.
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWPdaq
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
RT @nitrotake: バルサルタンvsプラセボのデザインだけど、ベースラインを見たら92%の人がACE-Iを使っているやん。 Val-HeFT Cohn JN,et al.N Engl J Med. 2001 Dec 6;345(23):1667-75.PMID:11…
RT @nitrotake: バルサルタンvsプラセボのデザインだけど、ベースラインを見たら92%の人がACE-Iを使っているやん。 Val-HeFT Cohn JN,et al.N Engl J Med. 2001 Dec 6;345(23):1667-75.PMID:11…
バルサルタンvsプラセボのデザインだけど、ベースラインを見たら92%の人がACE-Iを使っているやん。 Val-HeFT Cohn JN,et al.N Engl J Med. 2001 Dec 6;345(23):1667-75.PMID:11759645 https://t.co/Gbd90TjGeP
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Among patients with heart failure, valsartan was associated with lower rates of combined endpoint mainly related to decreased hospitalizations for HF compared with placebo with similar mortality #UMKCRCT https://t.co/Vo7vBvxjeB
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
Val-HeFT - 2001 - Valsartan vs placebo in LVF - ↓hospital admissions, ∅mortality - https://t.co/MmIlNWOFkS
@GiuseppeGalati_ @hvanspall @MarcoMetra @MicheleSenni @DrRajivsankar @rahatheart1 @AndreasGevaert @DrMarthaGulati @ShelleyZieroth @mirvatalasnag @DrNasrien @AspriAlexia @KTamirisaMD @MKIttlesonMD @HanCardiomd @pumpinghearts @IC_LaFe @ehj_ed @Vilavaite https://t.co/NHOrsvycqI #CardioTwitter
MV
た
S
DD
OB
DG
O
Dم
AM
G
NB
SH
A
あA
YU